drugset
drugset / Trial / NCT03952832

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

NCT03952832 ↗

Phase 2 Withdrawn City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2019-12-11
Primary completion
2021-06-11
Completion
2021-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule — Oral

Indications

smoldering plasma cell myeloma